New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

about

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

Item

http://www.wikidata.org/entity/Q49540457

description

2018 nî lūn-bûn

@nan

2018年の論文

@ja

2018年学术文章

@wuu

2018年学术文章

@zh

2018年学术文章

@zh-cn

2018年学术文章

@zh-hans

2018年学术文章

@zh-my

2018年学术文章

@zh-sg

2018年學術文章

@yue

2018年學術文章

@zh-hant

name

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

@en

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

@nl

type

Item

label

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

@en

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

@nl

prefLabel

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

@en

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

@nl

P1476

New Antibiotics in Development Target Highly Resistant Gram-Negative Organisms.

@en

P2093

Troy Kish

http://www.w3.org/2001/XMLSchema#string

P2860

Assessing the Efficacy and Safety of Eravacycline vs Ertapenem in Complicated Intra-abdominal Infections in the Investigating Gram-Negative Infections Treated With Eravacycline (IGNITE 1) Trial: A Randomized Clinical Trial.

In Vitro Activity of Eravacycline against Carbapenem-Resistant Enterobacteriaceae and Acinetobacter baumannii.

Phase 2, Dose-Ranging Study of Relebactam with Imipenem-Cilastatin in Subjects with Complicated Intra-abdominal Infection

Plazomicin Activity against 346 Extended-Spectrum-β-Lactamase/AmpC-Producing Escherichia coli Urinary Isolates in Relation to Aminoglycoside-Modifying Enzymes.

The ABCD's of β-lactamase nomenclature.

Prospective, randomized, double-blind, Phase 2 dose-ranging study comparing efficacy and safety of imipenem/cilastatin plus relebactam with imipenem/cilastatin alone in patients with complicated urinary tract infections.

In vitro activity of aztreonam-avibactam against a global collection of Gram-negative pathogens from 2012 and 2013.

In Vitro Activity of the Siderophore Cephalosporin, Cefiderocol, Against Carbapenem-Non-Susceptible and Multidrug-Resistant Isolates of Gram-Negative Bacilli Collected Worldwide in 2014-2016.

Identifying Spectra of Activity and Therapeutic Niches for Ceftazidime-Avibactam and Imipenem-Relebactam against Carbapenem-Resistant Enterobacteriaceae.

Antimicrobial Activities of Aztreonam-Avibactam and Comparator Agents against Contemporary (2016) Clinical Enterobacteriaceae Isolates.

P304

116-120

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2018-02-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29386869

http://www.w3.org/2001/XMLSchema#string

P932

5768301

http://www.w3.org/2001/XMLSchema#string